Table 3 Dosimetry comparison of [18F]-JK-PSMA-7 with other ¹⁸F-labled PSMA tracers

 Number of patients

10

3

4

5

 Used dosimetry software

QDOSE,

ABX-CRO, Germany

QDOSE,

ABX-CRO, Germany

MIM Software,

Cleveland, Ohio

ANALYZE,

BIR, Mayo Clinic

 Kidneys

1.76E−01

(6.52E−02 SD)

1.70E−01

(3.09E−02 SD)

9.45E−02

(n.a.)

2.84E−02

(3.81-03 SD)

 Lungs

1.10E−02

(2.16E−03 SD)

1.11E−02

(2.60E−04 SD)

1.08E−02

(n.a.)

2.45E−02

(2.99-03 SD)

 Liver

7.61E−02

(1.83E−02 SD)

6.02E−02

(6.24E−04 SD)

3.80E−02

(n.a.)

2.46E−02

(4.16-03 SD)

 Spleen

1.89E−02

(8.28E−03 SD)

7.39E−02

(2.96E−02 SD)

1.85E−02

(n.a.)

1.72E−02

(1.05E−03 SD)

 Salivary glands

4.68E−02

(1.50E−02 SD)

9.00E−02

(n.a.)

2.68E−02

(n.a.)

n.a.

 Effective dose

1.09E−02

(2.37E−03 SD)

2.20E−02

(2.08E−04 SD)

1.39E−02

(n.a.)

1.99E−02

(1.34E−03 SD)

 Kidneys

2.26E−01

(7.83E−02 SD)

2.64E−01

(5.03E−03 SD)

2.17E−01

(n.a.)

3.50E−02

(5.84E−03 SD)

 Lungs

4.39E−02

(7.16E−03 SD)

n.a.

3.70E−02

(n.a.)

1.09E–01

(1.87E−02 SD)

 Liver

5.70E−01

(1.31E −01 SD)

4.42E−01

(2.87E−02 SD)

2.60E−01

(n.a.)

1.59E−01

(3.29E−02 SD)

 Spleen

2.32E−02

(7.09E−03)

6.29E−02

(2.89E−02 SD)

2.07E−02

(n.a.)

1.01E−02

(8.92E−04 SD)

 Salivary glands

1.75E−02

(2.68E−03 SD)

1.37E−02

(3.64E−03 SD)

6.95E−03

(n.a.)

n.a.

 Whole-body

1.93E+00

(1.48E−01 SD)

2.64E+00

(0.00 SD)*

1.96E+00

(n.a.)

2.37E+00

(9.09E−02 SD)